Simplify Logo

Full-Time

Senior Manager

Fp&a

Posted on 6/27/2024

BlueRock Therapeutics

BlueRock Therapeutics

201-500 employees

Clinical stage cell therapy company

Hardware
Biotechnology

Senior, Expert

Cambridge, MA, USA

Category
Financial Planning and Analysis (FP&A)
Finance & Banking
Required Skills
Communications
Oracle
Requirements
  • Bachelor’s degree in Accounting, Finance, Business Administration or similar field
  • 7 or more years of experience in Accounting, Consulting, Financial Planning & Analysis (FP&A)
  • Experience in Life Sciences industry preferred
  • Proficiency in Microsoft Office Software Suite and Excel
  • Understanding of corporate finance
  • Knowledge of Oracle and Coupa applications
  • Strong interpersonal and communication skills
  • Problem-solving and analytical skills
  • Ability to work independently and in a team
  • Ability to maintain confidentiality
Responsibilities
  • Collaborate with FP&A team to develop Operating plan calendar
  • Partner with Department & Program leads for annual operating plan
  • Prepare budget/forecast templates and reports/presentations
  • Develop and manage Corporate financial models
  • Produce management reports on financial performance
  • Support R&D financial benchmarking initiatives
  • Prepare financial slides for board meetings
  • Coordinate with accounting department for month-end closes
  • Improve processes, tools, and systems for financial tracking
BlueRock Therapeutics

BlueRock Therapeutics

View

BlueRock Therapeutics is a clinical stage cell therapy company focused on harnessing the power of cell therapy to replace damaged or lost cells in order to create medicines for neurology, cardiology, and immunology indications. Their cell+gene platform utilizes cell differentiation technology to produce authentic cell therapies, with the potential to restore or regenerate lost function.

Company Stage

M&A

Total Funding

$807M

Headquarters

Toronto, Canada

Founded

2016

Growth & Insights
Headcount

6 month growth

7%

1 year growth

-1%

2 year growth

40%
INACTIVE